| 001 | 163868 | ||
| 005 | 20240229133510.0 | ||
| 024 | 7 | _ | |a 10.1007/s00405-020-06393-x |2 doi |
| 024 | 7 | _ | |a pmid:33000299 |2 pmid |
| 024 | 7 | _ | |a 0937-4477 |2 ISSN |
| 024 | 7 | _ | |a 1434-4726 |2 ISSN |
| 024 | 7 | _ | |a altmetric:107000457 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-02102 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Rühle, Alexander |0 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |b 0 |e First author |
| 245 | _ | _ | |a Radiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: results from a matched-pair analysis of a rare disease. |
| 260 | _ | _ | |a Heidelberg |c 2021 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1675086828_23510 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Jul;278(7):2537-2548 |
| 520 | _ | _ | |a This study analyzed survival and toxicity after (chemo)radiotherapy for primary salivary gland cancer patients aged ≥ 65 years and compared these results with younger patients using a matched-pair analysis.Twenty-nine elderly patients with primary salivary gland carcinomas treated with (chemo)radiotherapy from 2008 to 2020 at University of Freiburg Medical Center were analyzed for oncological outcomes and therapy-associated toxicities. Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method, and the influence of clinical parameters on patient outcomes was assessed. A matched-pair analysis was performed after matching with patients < 65 years.Nine patients (31.0%) received definitive (chemo)radiotherapy, and 20 patients (69.0%) were treated in the adjuvant setting. 2-year LRC, PFS and OS ranged at 82.4%, 53.7% and 71.8%, respectively. Smoking (HR 3.980, p = 0.020), reduced performance status (HR 3.735, p = 0.016) and higher comorbidity burden (HR 4.601, p = 0.005) correlated with inferior OS. Using a matched-pair analysis with younger patients, elderly patients exhibited a trend towards reduced OS (HR 3.015, p = 0.065), but not PFS (HR 1.474, p = 0.371) or LRC (HR 1.324, p = 0.633). Acute and chronic grade 3 toxicities occurred in 31.0% and 12.5% of elderly patients, respectively, and the matched-pair analysis revealed no significant differences between age groups regarding treatment-related toxicities.Treatment-related toxicities as well as LRC and PFS were comparable for salivary gland cancer patients undergoing radiotherapy. Therefore, concerns for more pronounced toxicities or reduced local/locoregional response rates should not guide treatment decisions in affected elderly patients. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Rothhaar, Sofie |b 1 |
| 700 | 1 | _ | |a Haehl, Erik |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Kalckreuth, Tobias |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Sprave, Tanja |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Stoian, Raluca |0 P:(DE-He78)75b4c256a6de824414938cf2aaeff88e |b 5 |
| 700 | 1 | _ | |a Zamboglou, Constantinos |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Gkika, Eleni |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Knopf, Andreas |b 8 |
| 700 | 1 | _ | |a Grosu, Anca-Ligia |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Nicolay, Nils |0 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd |b 10 |e Last author |
| 773 | _ | _ | |a 10.1007/s00405-020-06393-x |0 PERI:(DE-600)1459042-6 |n 7 |p 2537-2548 |t European archives of oto-rhino-laryngology and head & neck |v 278 |y 2021 |x 1434-4726 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:163868 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)75b4c256a6de824414938cf2aaeff88e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF3-890 |0 G:(DE-HGF)POF3-899 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-01-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2020-01-10 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR ARCH OTO-RHINO-L : 2018 |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2020-01-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-01-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-01-10 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2020-01-10 |
| 920 | 1 | _ | |0 I:(DE-He78)FR01-20160331 |k FR01 |l DKTK FR zentral |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)FR01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::